1. Volume 27, Issue 4, Pages 740-756 (April 2018)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 
Daniel J. Drucker 
Cell Metabolism 
Volume 27, Issue 4, Pages (April 2018)
DOI: /j.cmet
Copyright © 2018 Elsevier Inc. Terms and Conditions

2. Figure 1
Structure of Mammalian Proglucagon and the Proglucagon-Derived Peptides, and Principal Cell Types that Express the Canonical GLP-1 Receptor
GRPP, glicentin-related pancreatic polypeptide; IP-1 and IP-2, intervening peptides 1 and 2; GLP-1R, GLP-1 receptor; IEL, intraepithelial lymphocyte; VSM, vascular smooth muscle cell; SAN, sinoatrial node cell; EC, endothelial cell; EEC, enteroendocrine cell; MPGF, major proglucagon fragment.
Cell Metabolism  , DOI: ( /j.cmet )
Copyright © 2018 Elsevier Inc. Terms and Conditions

3. Figure 2
Pancreatic Endocrine and Exocrine Actions of GLP-1 on Islet and Acinar Cells
GLP-1 acts through the GLP-1 receptor (GLP-1R) expressed on islet β cells and δ cells to control insulin and somatostatin (SMS) secretion, respectively. SMS in turn inhibits glucagon secretion from islet α cells via the somatostatin-2 receptor (SSTR2).
Cell Metabolism  , DOI: ( /j.cmet )
Copyright © 2018 Elsevier Inc. Terms and Conditions

4. Figure 3 Actions of GLP-1 in the Context of Bariatric Surgery
GLP-1 levels rise following Roux-en-Y gastric bypass (RYGB) or after vertical sleeve gastrectomy (VSG).
Cell Metabolism  , DOI: ( /j.cmet )
Copyright © 2018 Elsevier Inc. Terms and Conditions

5. Figure 4
The Role of Microbial Products and Metabolites in the Control of GLP-1 Secretion
TLR, Toll-like receptor; IEL, intraepithelial lymphocyte; EEC, enteroendocrine cell.
Cell Metabolism  , DOI: ( /j.cmet )
Copyright © 2018 Elsevier Inc. Terms and Conditions

6. Figure 5
Representative Structures of Semaglutide, an Investigational Human GLP-1R Agonist, and an Investigational Tri-agonist Containing Amino Acids and Peptide Epitopes Enabling Activation of the Glucagon, GLP-1, and GIP Receptors
Lower panel depicts potential for GLP-1 receptor engagement with a small-molecule allosteric modulator, a biased peptide agonist, or a small molecule orally available GLP-1R agonist.
Cell Metabolism  , DOI: ( /j.cmet )
Copyright © 2018 Elsevier Inc. Terms and Conditions